BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Itepekimab: trial readouts and FDA decisions
1 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 3 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: Sanofi. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2027-02-17 est. | P3 | Sanofi SNY | NCT07424144 An Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis | Chronic Rhinosinusitis With Nasal Polyps | active not recruiting | 59 |
Readouts, last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-09-24 | P3 | Sanofi SNY | NCT06834360 A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusi | Chronic Rhinosinusitis With Nasal Polyps | active not recruiting | 216 |
| 2026-09-23 | P3 | Sanofi SNY | NCT06834347 A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusi | Chronic Rhinosinusitis With Nasal Polyps | active not recruiting | 231 |
| 2026-09-10 | P3 | Sanofi SNY | NCT06208306 A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD | Chronic Obstructive Pulmonary Disease | completed | 669 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.